SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, announced today that Iowa's Des Moines Register published an article reporting that its LUMA cervical imaging system is enhancing the effectiveness of cancer exams at the
Since Last July, researchers at the University of Iowa have used the LUMA Cervical Imaging System in more than 80 women - in conjunction with standard methods of detecting cervical cancer - to enhance their ability to locate cancer and precancerous disease.
Dr. Colleen Kennedy, primary investigator for the LUMA study at the university, said in the article that, "The hope is that LUMA will aid in the detection of precancer so that we don't have as much cancer and also aid in the detection of cancer so that it's identified early when treatment is better."
The trial at the University of Iowa is expected to be complete in 2010, with analysis from the first year of the study being available in September, according to Kennedy.
Jim Hitchin, CEO of SpectraScience, said, "We are pleased with the progress of the University's study and look forward to the preliminary results this September. We are encouraged to see an increasing level of attention in the healthcare community related to the LUMA cervical imaging system. Each year precancerous cervical tissue goes undiagnosed in 200,000 American women. The LUMA system, which provides an objective method of screening cervical tissue, can help to dramatically reduce this number. We believe this will improve the quality of healthcare to the patient and reduce overall costs by avoiding the expense of treating later stage cancers."
In the article, Kennedy also remarked, "It really doesn't add any discomfort or significant time to the patients. It literally adds maybe two minutes." For the complete article, go to http://www.spectrascience.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/SDOC0001.pdf
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
Contact: SpectraScience, Inc. Jim Hitchin, Chief Executive Officer (858) 847-0200 x 201 Hayden Communications Investor Relations Todd Pitcher (858)-518-1387
|SOURCE SpectraScience, Inc.|
Copyright©2009 PR Newswire.
All rights reserved